Gogo Inc (NASDAQ:GOGO) was the recipient of a large growth in short interest in January. As of March 31st, there was short interest totalling 10,866,166 shares, a growth of 22.4% from the March 14th total of 8,875,654 shares. Gogo Inc (NASDAQ:GOGO) stock performance was -7.70% in last session and finished the day at $16.79. Traded volume was 5.92million shares in the last session and the average volume of the stock remained 3.14million shares. Gogo Inc (NASDAQ:GOGO) insider ownership is 4.20%.

Galena Biopharma Inc (NASDAQ:GALE), which is a mid cap drug maker has seen its share price come under severe pressure of the bear market, ever since it reported on 17th March, that it has received communication from the SEC on the firm being investigated for breach of public trading rules. Galena Biopharma Inc (NASDAQ:GALE) dropped -8.74 percent to $1.88 Monday on volume of 5.85million shares. The intra-day range of the stock was $1.82 to $2.10. Galena Biopharma Inc (NASDAQ:GALE) has a market capitalization of $221.61million.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) recently presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s stock on Apr 14, 2014 reported a decrease of -13.72% to the closing price of $2.83. Its fifty two weeks range is $0.45 -$6.87. The total market capitalization recorded $233.08million. The overall volume in the last trading session was 5.29million shares. In its share capital, IDRA has 82.35million outstanding shares.

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced data from studies validating the immune-stimulatorymechanism of action of bavituximab and demonstrating that thecombination of a preclinical phosphatidylserine (PS)-targetingantibody with the immune checkpoint inhibitors anti-CTLA-4 oranti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma and colon cancer compared to anti-CTLA-4and PD-1 antibodies alone. On Monday, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) dropped -6.52% to close the day at $1.72. Company return on investment (ROI) is -126.10% and its monthly performance is recorded as -24.56%. Peregrine Pharmaceuticals (NASDAQ:PPHM) quarterly revenue growth is -3.37%.